Quantcast

Latest Denosumab Stories

2011-08-18 15:13:00

THOUSAND OAKS, Calif., Aug. 18, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present data from several Prolia® (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and Mineral Research (ASBMR) Annual Meeting in San Diego, Calif. from Sept. 16-20, 2011. "The breadth of data being...

2011-07-28 07:32:00

NEW YORK, July 28, 2011 /PRNewswire/ -- A study published by ITG this week revealed that U.S. oncologists expect Amgen's (NASDAQ: AMGN) recently approved XGEVA (denosumab) to become the top-prescribed drug over the next year for the prevention of skeletal-related events (SREs) in prostate cancer patients. Furthermore, although Novartis' (NYSE: NVS) Zometa (zoledronic acid) will likely remain the top-prescribed drug for preventing SREs in breast and lung cancer patients, physicians in the...

2011-07-15 06:01:00

THOUSAND OAKS, Calif., July 15, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. This approval of XGEVA applies to all 27 European Union (EU) member states. The EC also granted XGEVA...

2011-06-27 15:37:00

THOUSAND OAKS, Calif., June 27, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, XGEVA would be the first therapy licensed to prevent or delay the spread of cancer to the bone. The...

2011-05-20 06:30:00

THOUSAND OAKS, Calif., May 20, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a positive opinion for the marketing authorization of XGEVA(TM) (denosumab) for the prevention of skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. If approved by the...

2011-05-17 15:01:00

THOUSAND OAKS, Calif., May 17, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced primary results of a pivotal Phase 3 trial ('147) demonstrating that XGEVA(TM) (denosumab) significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone. Full results of the '147 study were presented for the first time today in a late-breaking plenary session at the American Urological...

2011-04-21 08:00:00

NEW YORK, April 21, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today outlined the Company's strategy, capital allocation plans and provided financial guidance for 2015 during a meeting with investors in New York. Kevin Sharer, chairman & CEO opened the meeting by outlining key elements of the Company's strategy: Bring medicines to market that advance treatment of serious illness; Make significant and sustained investment in research and development (R&D) and participate in a...

2011-03-23 15:06:00

THOUSAND OAKS, Calif., March 23, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) today announced new long-term data showing that during the fourth and fifth years of Prolia® (denosumab) treatment, postmenopausal women with osteoporosis receiving Prolia continued with further, statistically significant, year-over-year increases in lumbar spine and total hip bone mineral density (BMD), a key measurement of bone strength. The overall adverse event profile was similar for the...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related